277 related articles for article (PubMed ID: 8706739)
1. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
[TBL] [Abstract][Full Text] [Related]
2. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Gourlet P; Vilardaga JP; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
Peptides; 1996; 17(5):825-9. PubMed ID: 8844773
[TBL] [Abstract][Full Text] [Related]
3. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
[TBL] [Abstract][Full Text] [Related]
4. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
5. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
Du K; Nicole P; Couvineau A; Laburthe M
Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
[No Abstract] [Full Text] [Related]
6. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
7. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
10. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.
Vilardaga JP; De Neef P; Di Paolo E; Bollen A; Waelbroeck M; Robberecht P
Biochem Biophys Res Commun; 1995 Jun; 211(3):885-91. PubMed ID: 7598719
[TBL] [Abstract][Full Text] [Related]
12. Development of high affinity selective VIP1 receptor agonists.
Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
[TBL] [Abstract][Full Text] [Related]
13. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
[TBL] [Abstract][Full Text] [Related]
14. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality.
Di Paolo E; Vilardaga JP; Petry H; Moguilevsky N; Bollen A; Robberecht P; Waelbroeck M
Peptides; 1999; 20(10):1187-93. PubMed ID: 10573290
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.
Perret J; Van Craenenbroeck M; Langer I; Vertongen P; Gregoire F; Robberecht P; Waelbroeck M
Biochem J; 2002 Mar; 362(Pt 2):389-94. PubMed ID: 11853547
[TBL] [Abstract][Full Text] [Related]
16. Identification of a VIP-specific receptor in guinea pig tenia coli.
Teng BQ; Grider JR; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
[TBL] [Abstract][Full Text] [Related]
17. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
18. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.
Park CG; Ganguli SC; Pinon DI; Hadac EM; Miller LJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):682-8. PubMed ID: 11046106
[TBL] [Abstract][Full Text] [Related]
19. Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.
Robberecht P; Di Paolo E; Moguilevsky N; Bollen A; Waelbroeck M
Ann N Y Acad Sci; 2000; 921():362-5. PubMed ID: 11193853
[No Abstract] [Full Text] [Related]
20. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]